blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3062782

EP3062782 - COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  26.08.2022
Database last updated on 24.09.2024
FormerExamination is in progress
Status updated on  12.10.2018
Most recent event   Tooltip26.08.2022Application deemed to be withdrawnpublished on 28.09.2022  [2022/39]
Applicant(s)For all designated states
Pharnext
11-13 Rue René Jacques
92130 Issy-les-Moulineaux / FR
[2019/20]
Former [2016/36]For all designated states
Pharnext
11 Rue des Peupliers
92130 Issy les Moulineaux / FR
Inventor(s)01 / COHEN, Daniel
132 Rue des Tennerolles
F-92210 Saint Cloud / FR
02 / CHUMAKOV, Ilya
691 Rue de la Noue
F-77000 Vaux le Penil / FR
03 / NABIROCHKIN, Serguei
49 Avenue de Sully Prud'homme
F-92290 Chatenay Malabry / FR
04 / HAJJ, Rodolphe
1 bis Rue Raymond Greban
F-78100 Saint Germain En Laye / FR
 [2016/36]
Representative(s)Cabinet Becker et Associés
25, rue Louis le Grand
75002 Paris / FR
[2016/36]
Application number, filing date14790106.029.10.2014
[2016/36]
WO2014EP73201
Priority number, dateWO2013EP7272830.10.2013         Original published format: PCT/EP2013/072728
EP2014016673430.04.2014         Original published format: EP 14166734
[2016/36]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015063140
Date:07.05.2015
Language:EN
[2015/18]
Type: A1 Application with search report 
No.:EP3062782
Date:07.09.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 07.05.2015 takes the place of the publication of the European patent application.
[2016/36]
Search report(s)International search report - published on:EP07.05.2015
ClassificationIPC:A61K31/122, A61K31/137, A61K31/138, A61K31/16, A61K31/197, A61K31/216, A61K31/4164, A61K31/42, A61K31/437, A61K31/44, A61K31/445, A61K31/495, A61K31/519, A61K31/53, A61K31/55
[2016/36]
CPC:
A61K31/519 (EP,US); A61K31/122 (EP,US); A61K31/135 (US);
A61K31/137 (EP,US); A61K31/138 (EP,US); A61K31/155 (EP,US);
A61K31/16 (EP,US); A61K31/196 (US); A61K31/197 (EP,US);
A61K31/216 (EP,US); A61K31/24 (US); A61K31/4164 (EP,US);
A61K31/42 (EP,US); A61K31/422 (EP,US); A61K31/437 (EP,US);
A61K31/44 (EP,US); A61K31/445 (EP,US); A61K31/4745 (US);
A61K31/495 (EP,US); A61K31/50 (US); A61K31/53 (EP,US);
A61K31/55 (EP,US); A61K31/7004 (EP,US); A61K45/06 (US) (-)
C-Set:
A61K31/122, A61K2300/00 (US,EP);
A61K31/137, A61K2300/00 (US,EP);
A61K31/138, A61K2300/00 (US,EP);
A61K31/155, A61K2300/00 (EP,US);
A61K31/16, A61K2300/00 (US,EP);
A61K31/197, A61K2300/00 (EP,US);
A61K31/216, A61K2300/00 (US,EP);
A61K31/4164, A61K2300/00 (US,EP);
A61K31/422, A61K2300/00 (EP,US);
A61K31/42, A61K2300/00 (EP,US);
A61K31/437, A61K2300/00 (US,EP);
A61K31/445, A61K2300/00 (US,EP);
A61K31/44, A61K2300/00 (US,EP);
A61K31/495, A61K2300/00 (US,EP);
A61K31/519, A61K2300/00 (EP,US);
A61K31/53, A61K2300/00 (US,EP);
A61K31/55, A61K2300/00 (US,EP);
A61K31/7004, A61K2300/00 (EP,US)
(-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/36]
TitleGerman:ZUSAMMENSETZUNGEN, VERFAHREN UND VERWENDUNGEN ZUR BEHANDLUNG VON DIABETES UND ZUGEHÖRIGEN ERKRANKUNGEN DURCH REGELUNG DES BLUTZUCKERWERTS[2016/36]
English:COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL[2016/36]
French:COMPOSITIONS, PROCÉDÉS ET UTILISATIONS POUR LE TRAITEMENTS DE DIABÈTE ET D'ÉTATS ASSOCIÉS EN RÉGULANT LE NIVEAU DE GLYCÉMIE[2016/36]
Entry into regional phase18.05.2016National basic fee paid 
18.05.2016Designation fee(s) paid 
18.05.2016Examination fee paid 
Examination procedure18.05.2016Amendment by applicant (claims and/or description)
18.05.2016Examination requested  [2016/36]
11.10.2018Despatch of a communication from the examining division (Time limit: M06)
05.03.2019Reply to a communication from the examining division
21.01.2020Despatch of a communication from the examining division (Time limit: M04)
28.05.2020Reply to a communication from the examining division
28.10.2020Despatch of a communication from the examining division (Time limit: M04)
26.02.2021Reply to a communication from the examining division
03.05.2022Application deemed to be withdrawn, date of legal effect  [2022/39]
24.05.2022Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2022/39]
Fees paidRenewal fee
03.10.2016Renewal fee patent year 03
17.10.2017Renewal fee patent year 04
11.10.2018Renewal fee patent year 05
21.10.2019Renewal fee patent year 06
23.10.2020Renewal fee patent year 07
Penalty fee
Additional fee for renewal fee
31.10.202108   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]US5019591  (GARDNER THOMAS W [US], et al) [Y] 1-12 * claim 1 *;
 [Y]US2003162754  (LIGON BROOKE [US]) [Y] 1-12 * paragraph [0012] - paragraph [0019] * * paragraphs [0030] , [0 34] * * claims 3,5,7,9,10-13 *;
 [Y]WO2004011003  (PHARMACIA ITALIA SPA [IT], et al) [Y] 1-12 * Summary * * Claims *;
 [Y]US2005025714  (DUGGER HARRY A [US]) [Y] 1-12 * paragraphs [0039] , [0 40] , [0 43] * * claims 40, 41, 44, 96, 97, 100 *;
 [Y]US2006004050  (SPEICHER BRIAN T [US], et al) [Y] 1-12 * Detailed Description of the Invention * * example 2 ** claims 1-4, 10 *;
 [Y]EP1884513  (JAPAN TOBACCO INC [JP]) [Y] 1-12 * p. 42, items 23 and 26 * * paragraphs [0197] , [ 198] * * claims 23, 26 *;
 [Y]US2008213362  (SOLOMON LAWRENCE [US]) [Y] 1-12 * paragraphs [0006] , [00 8] , [0 22] , [0 24] - [0026] * * claims 9-12, 23-28 *;
 [Y]US2011046046  (HARA HIROSHI [JP], et al) [Y] 1-12 * paragraphs [0017] , [0 19] , [0 53] , [0067] , [0 73] * * claims 1, 2, 4 * * figures *;
 [IY]  - ABEDULLA KHAN K; SATYANARAYANA S; ESWAR KUMAR K; ANUPAMA K, "Pharmacodynamic drug interaction of mexiletine with metformin in rats", RESEARCH JOURNAL OF PHARMACEUTICAL, BIOLOGICAL AND CHEMICAL SCIENCES, (20120701), vol. 3, no. 3, ISSN 0975-8585, pages 905 - 911, XP055161335 [I] 1,3-12 * the whole document * * in particular * * abstract * * 'Study in normal rats' * * 'Results and Discussion' * [Y] 1-12
 [Y]  - DUNN C J ET AL, "A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE IN NON-INSULIN-DEPENDENT DIABETES MELLITUS", DRUGS, ADIS INTERNATIONAL LTD, NZ, (19950501), vol. 49, no. 5, doi:10.2165/00003495-199549050-00007, ISSN 0012-6667, pages 721 - 749, XP000921043 [Y] 1-12 * the whole document * * in particular p. 738 et seqq. *

DOI:   http://dx.doi.org/10.2165/00003495-199549050-00007
 [Y]  - "Metformin/Repaglinide (PrandiMet) for type 2 diabetes", THE MEDICAL LETTER ON DRUGS AND THERAPEUTICS, USA, (20090601), vol. 51, no. 1313, ISSN 1523-2859, pages 41 - 43, XP009177448 [Y] 1-12 * the whole document * * in particular * * page 41, column 2 * * 'Fixed-Dose Combinations' * * page 42 * * table 1 *
 [Y]  - FREYRIA J, "Clinical trial with an antiischemic drug in atherosclerotic and diabetic arteriopathies = Essai de la thérapeutique anti-ischémique dans le traitement des artériopathies de surchage", GAZETTE MEDICALE DE FRANCE, PARIS, FR, (19750101), vol. 82, no. 16, ISSN 0016-5557, page 1989, XP009175880 [Y] 1-12 * page 1989 * * page 1990, column 1, paragraph 1 * * page 1993, column 2, paragraph 1 *
 [A]  - SALEM H ET AL, "FENSPIRIDE A NONSYMPATHOMIMETIC BRONCHO DILATOR WITH ANTI ALLERGIC ACTIVITY", ARCHIVES INTERNATIONALES DE PHARMACODYNAMIE ET DE THERAPIE, HEYMANS INSTITUTE OF PHARMACOLOGY, GHENT, BE, (19710101), vol. 193, no. 1, ISSN 0003-9780, pages 111 - 123, XP009177441 [A] 1-12 * the whole document * * in particular * * abstract *
 [Y]  - WALKER B R ET AL, "HYPERKALEMIA AFTER TRIAMTERENE IN DIABETIC PATIENTS", CLINICAL PHARMACOLOGY AND THERAPEUTICS, NATURE PUBLISHING GROUP, US, (19720101), vol. 13, no. 5, part 1, ISSN 0009-9236, pages 643 - 651, XP009168825 [Y] 1-12 * the whole document * * in particular * * abstract * * page 644, column 1, paragraph 2 * * Results. Triamterene Discussion *

DOI:   http://dx.doi.org/10.1002/cpt1972135part1643
 [A]  - YAMASHITA S ET AL, "GENERAL PHARMACOLOGICAL ACTIVITIES OF N-2 METHYL-3-CHLOROPHENYL ANTHRANILIC-ACID GEA-6414", IGAKKAI ZASSHI -JOURNAL OF MEDICAL SOCIETY OF TOHO UNIVERSITY, TOHO DAIGAKU IGAKUBU IGAKKAI, TOKYO, JP, (19810101), vol. 28, no. 4, ISSN 0040-8670, pages 685 - 697, XP009177377 [A] 1-12 * abstract *
 [Y]  - FRANCO F ET AL, "P2165 Levosimendan is beneficial in diabetics with acute heart failure", EUROPEAN HEART JOURNAL, OXFORD UNIVERSITY PRESS, GB, (20030301), vol. 24, no. 5, doi:10.1016/S0195-668X(03)95159-1, ISSN 0195-668X, page 407, XP004531081 [Y] 1-12 * abstract *

DOI:   http://dx.doi.org/10.1016/S0195-668X(03)95159-1
ExaminationUS2008188457
 WO2008112167
    - RAGUCCI KELLY R ET AL, "Olanzapine-induced diabetic ketoacidosis", ANNALS OF PHARMACOTHE, HARVEY WHITNEY BOOKS COMPANY, US, (20011201), vol. 35, no. 12, doi:10.1345/APH.1A157, ISSN 1060-0280, pages 1556 - 1558, XP009092538

DOI:   http://dx.doi.org/10.1345/aph.1A157
    - J. Shang ET AL, "Metformin-stimulated Mannose Transport in Dermal Fibroblasts", Journal of Biological Chemistry, (20031217), vol. 279, no. 11, doi:10.1074/jbc.M310837200, ISSN 0021-9258, pages 9703 - 9712, XP055160708

DOI:   http://dx.doi.org/10.1074/jbc.M310837200
by applicant   - VAN BELLE, T.L.; K.T. COPPIETERS; M.G. VON HERRATH, "Type 1 diabetes: etiology, immunology, and therapeutic strategies", PHYSIOL REV, (2011), vol. 91, no. 1, doi:doi:10.1152/physrev.00003.2010, pages 79 - 118, XP002717471

DOI:   http://dx.doi.org/10.1152/physrev.00003.2010
    - MAGGIO, C.A.; F.X. PI-SUNYER, "The prevention and treatment of obesity. Application to type 2 diabetes", DIABETES CARE, (1997), vol. 20, no. 11, pages 1744 - 66
    - STUMVOLL, M.; B.J. GOLDSTEIN; T.W. VAN HAEFTEN, "Type 2 diabetes: principles of pathogenesis and therapy", LANCET, (2005), vol. 365, no. 9467, doi:doi:10.1016/S0140-6736(05)61032-X, pages 1333 - 46, XP025276573

DOI:   http://dx.doi.org/10.1016/S0140-6736(05)61032-X
    - BODEN, G., "Role of fatty acids in the pathogenesis of insulin resistance and NIDDM", DIABETES, (1997), vol. 46, no. 1, pages 3 - 10
    - GOLDSTEIN, B.J., "Insulin resistance as the core defect in type 2 diabetes mellitus", AM J CARDIOL, (2002), vol. 90, no. 5A, pages 3G - 10G
    - BESSAC, L., "Unmet medical needs and therapeutic goals in the treatment of type 2 diabetes", CURR OPIN INVESTIG DRUGS, (2003), vol. 4, no. 10, pages 1173 - 8
    - ROLLA, A.R., "Starting insulin strategies for patients with an inadequate response to oral therapy", DIABETES OBES METAB, (2009), vol. 11, no. 5, pages 6 - 9
    - YANG, Y.X.; S. HENNESSY; J.D. LEWIS, "Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients", GASTROENTEROLOGY, (2004), vol. 127, no. 4, doi:doi:10.1053/j.gastro.2004.07.011, pages 1044 - 50, XP005313020

DOI:   http://dx.doi.org/10.1053/j.gastro.2004.07.011
    - NATHAN, D.M. ET AL., "Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes", DIABETES CARE, (2009), vol. 32, no. 1, pages 193 - 203
    - ETTMAYER, P.; AMIDON, G. L.; CLEMENT, B.; TESTA, B, "Lessons learned from marketed and investigational prodrugs", J. MED. CHEM., (2004), vol. 47, doi:doi:10.1021/jm0303812, pages 2393 - 2404, XP001537347

DOI:   http://dx.doi.org/10.1021/jm0303812
    - BEAUMONT, K.; WEBSTER, R.; GARDNER, I.; DACK, K, "Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist", CURR. DRUG METAB, (2003), vol. 4, doi:doi:10.2174/1389200033489253, pages 461 - 485, XP008058352

DOI:   http://dx.doi.org/10.2174/1389200033489253
    - HEIMBACH, T. ET AL., "Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs", INT. J. PHARM., (2003), vol. 261, doi:doi:10.1016/S0378-5173(03)00287-4, pages 81 - 92, XP002349277

DOI:   http://dx.doi.org/10.1016/S0378-5173(03)00287-4
    - YANG, C. Y.; DANTZIG, A. H.; PIDGEON, C., "Intestinal peptide transport systems and oral drug availability", PHARM. RES., (1999), vol. 16, doi:doi:10.1023/A:1018982505021, pages 1331 - 1343, XP000910009

DOI:   http://dx.doi.org/10.1023/A:1018982505021
    - STEFFANSEN, B. ET AL., "Intestinal solute carriers: an overview of trends and strategies for improving oral drug absorption", EUR. J. PHARM. SCI., (2004), vol. 21, pages 3 - 16, XP002329331
    - PEZRON, I. ET AL., "Prodrug strategies in nasal drug delivery", EXPERT OPIN. THER. PAT., (2002), vol. 12, no. 3, pages 331 - 340
    - STELLA, V., "J. Prodrugs as therapeutics", EXPERT OPIN. THER. PAT., (2004), vol. 14, pages 277 - 280
    - STELLA, V. J.; NTI-ADDAE, K. W, "Prodrug strategies to overcome poor water solubility", ADV. DRUG DELIV. REV., (2007), vol. 59, doi:doi:10.1016/j.addr.2007.05.013, pages 677 - 694, XP022211987

DOI:   http://dx.doi.org/10.1016/j.addr.2007.05.013
    - "Prodrugs As Novel Drug Delivery Systems", ACS Symposium Series, AMERICAN CHEMICAL SOCIETY, (1975), page 31
    - ASFARI M.; JANJIC D.; MEDA P.; LI G.; HALBAN P.A.; WOLLHEIM C.B, "Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines", ENDOCRINOLOGY, (1992), vol. 130, pages 167 - 78
    - FRANKFURT O.S.; KRISHAN A, "Enzyme-linked immunosorbent assay (ELISA) for the specific detection of apoptotic cells and its application to rapid drug screening", J IMMUNOL METHODS, (2001), vol. 253, doi:doi:10.1016/S0022-1759(01)00387-8, pages 133 - 144, XP004241366

DOI:   http://dx.doi.org/10.1016/S0022-1759(01)00387-8
    - FRYER L.G.; HAJDUCH E.; RENCUREL F.; SALT I.P.; HUNDAL H.S.; HARDIE D.G.; CARLING D, "Activation of glucose transport by AMP-activated protein kinase via stimulation of nitric oxide synthase", DIABETES, (200012), vol. 49, no. 12, doi:doi:10.2337/diabetes.49.12.1978, pages 1978 - 85, XP009008297

DOI:   http://dx.doi.org/10.2337/diabetes.49.12.1978
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.